Testing a new combination therapy for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, RZ-001, combined with valganciclovir, atezolizumab, and bevacizumab for people with hepatocellular carcinoma (a type of liver cancer). The goal is to see if this combination is safe and works better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (18 years or older).
- You must have been diagnosed with hepatocellular carcinoma (liver cancer) at a specific stage (B or C).
- Your tumor must have a protein called hTERT, which will be checked during screening.
- You must be in fairly good health (ECOG score of 0 or 1) and have a Child-Pugh score of A, meaning your liver is working well.
- You must have a life expectancy of at least 3 months.
- You cannot have moderate or severe fluid buildup in your belly (ascites), a history of hepatic encephalopathy (liver-related brain issues), or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining three drugs (atezolizumab, bevacizumab, and tocilizumab) to see if they can help people with advanced liver cancer that cannot be removed with surgery. It aims to shrink tumors and improve outcomes for patients who have not had prior systemic therapy.
This trial tests a new way to find and treat liver cancer that cannot be removed by surgery. First, a special dye (RYZ811) is used to see if your cancer cells have a marker called GPC3. If they do, you may receive a targeted radiation treatment (RYZ801) that seeks out those cells. This trial is for people whose liver cancer has grown despite receiving at least one prior therapy.
This study looks at how well the combination of atezolizumab and bevacizumab works for people with liver cancer that has come back or spread, based on real patient records from a hospital registry.
This trial tests a new treatment called RZ-001 combined with an antiviral drug (valganciclovir) for people with glioblastoma, a serious brain tumor. The goal is to see if the combination is safe and can help shrink or slow the tumor.
This trial tests a new drug combination (rilvegostomig plus bevacizumab, with or without tremelimumab) as a first treatment for people with advanced liver cancer (HCC) that cannot be removed by surgery or treated with local therapies. It aims to see if these combinations help shrink tumors or slow disease progression.
This trial tests a combination of two investigational drugs (PM8002 and PM1009) as a first treatment for advanced liver cancer that cannot be surgically removed. The goal is to see if this new treatment works better than current options.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.